Bull Call Spreads
[Debit]
Bull Put Spreads
[Credit]
Bear Call Spreads
[Credit]
Bear Put Spreads
[Debit]
Call Butterflies
[Short ATM, Long OTM]
Call Butterflies
[Long ATM, Short OTM]
Put Butterflies
[Short ATM, Long OTM]
Put Butterflies
[Long ATM, Short OTM]
Iron Butterflies
[Short ATM, Long OTM]
Iron Butterflies
[Long ATM, Short OTM]
Iron Condors
[Long Inner, Short Outer]
Iron Condors
[Short Inner, Long Outer]
Straddles
[At-The-Money]
Get Cash Back and $0 Commissions
+ The Power of TradeStation
Business Wire 14-May-2018 2:52 PM
The "Drug Overview: QVM149" report has been added to ResearchAndMarkets.com's offering.
QVM149 (Novartis) is a fixed triple combination product consisting of a long-acting muscarinic antagonist (glycopyrronium bromide), a long-acting beta 2 agonist (LABA) (indacaterol), and an inhaled corticosteroid (ICS) (mometasone furoate). QVM149 is in Phase III development for the treatment of moderate to severe asthma uncontrolled with standard ICS/LABA therapies.
Key Topics Covered:
Product Profiles
QVM149: Asthma
List of Figures
Figure 1: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 2: Symbicort for asthma - SWOT analysis
List of Tables
Table 1: QVM149 drug profile
Table 2: QVM149 Phase III trials in asthma
Table 3: QVM149 sales for asthma across Japan and the five major EU markets, by country (NYSE:M), 2017-26
For more information about this report visit https://www.researchandmarkets.com/research/kj52wl/qvm149_novartis?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180514006238/en/